Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
After 1 month of treatment in pernicious anemia patients, the once weekly dosing of 500 mcg B12 intranasal gel resulted in a statistically significant increase in B12 levels when compared to a once monthly 100 mcg IM dose
Verdict for Ozempic (in use): Safe
So injecting beyond a certain point may cause your cells to fight off the excess B12 so hard that it might reduce the amount of active cellular B12 - probably not to dangerous levels, but possibly sufficient to trigger some symptoms
Pigmentation pathway studies: Investigation of melanin production mechanisms
Neutraliza el potencial txico de muchas sustancias del organismo, las hace solubles en agua para ser eliminadas